Medicine
Dibasic and Monobasic 1180 mg/1120 mg per 250 mL injection
Dibasic and Monobasic 1180 mg/1120 mg per 250 mL injection is a generic prescription medicine for intravenous use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F).
Key facts
- Active ingredient (INN)
- Dibasic and Monobasic
- Brand
- Sold under the generic name
- Strength
- 1180 mg/1120 mg per 250 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 30 pouches of 250 mL
- Manufacturer
- Fresenius Kabi
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 June 2025
- Identifiers
- RxCUI 2688947, 2716829DailyMed set ID 357c3020-ea6f-4401-a2e7-cebb82b03144NDC 65219-658Application NDA212832
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 pouch in 1 carton / 1 bag in 1 pouch / 250 mL in 1 bag | 65219-658-25 | Fresenius Kabi | 15 June 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Dibasic and Monobasic
Clinical summary
Dibasic and Monobasic is a fixed-dose combination of an osmotic laxative and a potassium salt indicated as a source of phosphorus, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Dibasic and Monobasic for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Dibasic and MonobasicFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Potassium Phosphates prescribing information (Civica) · U.S. National Library of Medicine, DailyMed
Need Dibasic and Monobasic 1180 mg/1120 mg per 250 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.